Loading…
H.R. 8269119th CongressIn committeeLatest action Apr 14, 2026Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
HR 8269 requires drug labels to identify manufacturers of active ingredients, finished products, and any packer or distributor involved.
60-second read · 4 questions answered below
HR 8269 would require prescription and over-the-counter drug labels to identify the original manufacturer of each active ingredient, the manufacturer of the finished drug product, and any packer or distributor involved. This information could appear directly on the label or be accessible through a barcode or QR code linked to an online database. Manufacturers would also have to provide this information in paper form upon request, and companies would have at least one year after FDA finalizes its rules to comply.
The bill affects drug manufacturers, packagers, and distributors that sell medications in the United States, including companies that source ingredients from overseas. Consumers and pharmacists would also be affected, gaining easier access to information about where a drug and its ingredients were produced.
People who want to know whether drug ingredients come from specific countries, such as China or India, where a large share of pharmaceutical ingredients are currently manufactured, would have a clearer way to find that information. The bill also exempts finished drug products that meet the new labeling requirements from a separate customs marking rule, since the drug label would already carry the required location information.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.